| 0.05 -0.019 (-27.95%) | 12-05 15:31 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.03 | 1-year : | 0.04 |
| Resists | First : | 0.03 | Second : | 0.03 |
| Pivot price | 0.03  |
|||
| Supports | First : | 0.02 | Second : | 0.01 |
| MAs | MA(5) : | 0.02 |
MA(20) : | 0.03 |
| MA(100) : | 0.21 |
MA(250) : | 1.17 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 31.9 |
D(3) : | 41.9 |
| RSI | RSI(14): 37.6 |
|||
| 52-week | High : | 6.94 | Low : | 0.02 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CFRX ] has closed above bottom band by 14.2%. Bollinger Bands are 90.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 44 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.04 - 0.04 | 0.04 - 0.04 |
| Low: | 0.03 - 0.03 | 0.03 - 0.03 |
| Close: | 0.03 - 0.03 | 0.03 - 0.03 |
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.
Mon, 22 Apr 2024
ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program for ... - The Globe and Mail
Mon, 22 Apr 2024
ContraFect Corporation Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase ... - The Globe and Mail
Mon, 22 Apr 2024
ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants - The Globe and Mail
Mon, 22 Apr 2024
ContraFect Corporation Prices Public Offering of Common Stock - The Globe and Mail
Mon, 16 Oct 2023
Why Is ContraFect (CFRX) Stock Up 23% Today? - InvestorPlace
Thu, 17 Aug 2023
CFRX: CF-370 IND to be Filed in 3Q23… - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 11 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 6.1 (%) |
| Shares Short | 116 (K) |
| Shares Short P.Month | 14 (K) |
| EPS | -10.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.55 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -117.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -36 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -0.06 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|